Efficacy and safety analyses of the TALENT trial (GETNE 1509): a phase II study of lenvatinib in patients (pts) with advanced G1/G2 pancreatic (panNETs) and gastrointestinal (ginets) neuroendocrine tumors
Capdevila, J Bongiovanni, A Hernando, J Spada, F Lopez, C Teule, A Merino, X Lamarca, Angela Tafuto, S Custodio, A
Capdevila, J
Bongiovanni, A
Hernando, J
Spada, F
Lopez, C
Teule, A
Merino, X
Lamarca, Angela
Tafuto, S
Custodio, A
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Capdevila J, Bongiovanni A, Hernando J, Spada F, Lopez C, Teule A, et al. Efficacy and safety analyses of the TALENT trial (GETNE 1509): a phase II study of lenvatinib in patients (pts) with advanced G1/G2 pancreatic (panNETs) and gastrointestinal (ginets) neuroendocrine tumors. Neuroendocrinology. 2019;108:168.